Carolina Cuéllar-García

TL;DR: In CLL, COVID-19 severity increases with age; antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

TL;DR: In this paper, the authors investigated the impact of CLL-directed treatments on the course of Coronavirus disease 2019 (COVID-19) and found that patients with chronic lymphocytic leukemia (CLL) may be more susceptible to the disease due to age, disease, and treatment-related immunosuppression.

TL;DR: In this article , the authors assess the risk of thrombosis and bleeding in patients with chronic lymphocytic leukemia (CLL) affected by severe COVID-19, using RT-PCR.

TL;DR: In this paper , the authors presented a COVID-19 related poor outcomes, including throuposis and death, due to the advanced age, presence of com-bidities, etc.

TL;DR: In this article , the authors showed that patients with chronic lymphocytic leukemia (CLL) have a very high risk of severe Coronavirus disease 19 (COVID19) and identified age, CLL-directed treatment, and cardiac failure as risk factors of overall survival.